Dr. Brown on PI3 Kinase Inhibitors in CLL

Jennifer Brown, MD, PhD
Published: Thursday, Mar 02, 2017



Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses PI3 kinase inhibitors in patients with chronic lymphocytic leukemia (CLL).

There are 2 drugs that inhibit PI3 kinase delta that are in registration trials, Brown explains. The first, duvelisib, also inhibits PI3 kinase gamma, meaning it can target T cells and neutrophils, which has had high activity in CLL.

The other drug, TGR-1202, has had to go through dosing modifications and be reformulated to achieve effective pharmacokinetics in patients. The number of patients on those doses and the duration is relatively limited but they have seen beneficial response rates, Brown states.
 
SELECTED
LANGUAGE


Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses PI3 kinase inhibitors in patients with chronic lymphocytic leukemia (CLL).

There are 2 drugs that inhibit PI3 kinase delta that are in registration trials, Brown explains. The first, duvelisib, also inhibits PI3 kinase gamma, meaning it can target T cells and neutrophils, which has had high activity in CLL.

The other drug, TGR-1202, has had to go through dosing modifications and be reformulated to achieve effective pharmacokinetics in patients. The number of patients on those doses and the duration is relatively limited but they have seen beneficial response rates, Brown states.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x